Biologic Therapies for Psoriasis

被引：2

作者：

de Felice, Catia ^{[1
]}

Ardigo, Marco ^{[1
]}

Berardesca, Enzo ^{[1
]}

机构：

[1] San Gallicano Dermatol Inst, I-00144 Rome, Italy

来源：

JOURNAL OF RHEUMATOLOGY | 2009年 / 36卷

关键词：

TUMOR NECROSIS FACTOR INHIBITORS; PSORIASIS; BIOLOGIC THERAPIES; CHRONIC PLAQUE PSORIASIS; PHASE-III; EFALIZUMAB THERAPY; CONTROLLED-TRIAL; MODERATE; ETANERCEPT; EFFICACY; SAFETY;

D O I：

10.3899/jrheum.090228

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Psoriasis is a common chronic inflammatory skin disease that may lead to disability and significant effects on patients' quality of life. A challenge in psoriasis management is to use an effective therapy early in the disease course in order to achieve a safe and well tolerated maintenance of remission with an improvement of both skin and joint manifestations. Recent advances in knowledge of the pathogenesis of psoriasis helped develop targeted treatment options that may be effective and well tolerated over long periods of administration. thus improving the patient's quality of life. These novel "biologic" agents specifically target tumor necrosis factor-alpha (infliximab, etanercept, and adalimumab) or T cells (efalizumab). J Rheumatol 2009;36 Suppl 83:62-64; doi:10.3899/jrheum.090228)

引用

页码：62 / 64

页数：3

共 22 条

[1] Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
Antoni, CE
Kavanagh, A
Kirkham, B
Tutuncu, Z
Burmester, GR
Schneider, U
Furst, DE
Molitor, J
Keystone, E
Gladman, D
Manger, B
Wassenberg, S
Weier, R
Wallace, DJ
Weisman, MH
Kalden, JR
Smolen, J
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (04): : 1227 - 1236
[2] BACKER DE, 2004, GASTROENTEROL DISORD, V4, P196
[3] CHEN DM, 2004, J AM ACAD DERMATO 2, V50
[4] de Rie Menno A, 2004, Dermatol Ther, V17, P341, DOI 10.1111/j.1396-0296.2004.04037.x
[5] Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
Ellis, CN
Krueger, GG
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (04) : 248 - 255
[6] Griffiths C E, 2000, Health Technol Assess, V4, P1
[7] Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial
Leonardi, CL
Papp, KA
Gordon, KB
Menter, A
Feldman, SR
Caro, I
Walicke, A
Compton, PG
Gottlieb, AB
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : 425 - 433
[8] Etanercept as monotherapy in patients with psoriasis
Leonardi, CL
Powers, JL
Matheson, RT
Goffe, BS
Zitnik, R
Wang, A
Gottlieb, AB
Bagel, J
Camisa, C
Caro, I
DiGiovanna, JJ
Dunlap, FF
Elewski, BE
Gribetz, CE
Farber, HF
Feldman, SR
Frankel, EH
Gaspari, AA
Goodman, JJ
Gordon, KB
Hampel, FC
Herdener, RS
Hoffman, MD
Humeniuk, JM
Johnson, SM
Kang, S
Kimball, AB
Kirsner, RS
Korman, NJ
Krueger, GG
Kuwahara, RT
Lebwohl, M
Ling, MR
Liu, DC
Lowe, N
McCall, CO
Menter, A
Miller, BH
Moore, JK
Nayak, AS
Ratner, PH
Savin, RC
Shupack, JL
Smith, SL
Stone, SP
Swinehart, JM
Taborn, J
Tschen, EH
Weinstein, GD
Werth, VP
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) : 2014 - 2022
[9] Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis
Menter, A
Gordon, K
Carey, W
Hamilton, T
Glazer, S
Caro, I
Li, N
Gulliver, W
[J]. ARCHIVES OF DERMATOLOGY, 2005, 141 (01) : 31 - 38
[10] A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis
Menter, Alan
Feldman, Steven R.
Weinstein, Gerald D.
Papp, Kim
Evans, Robert
Guzzo, Cynthia
Li, Shu
Dooley, Lisa T.
Arnold, Cynthia
Gottlieb, Alice B.
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) : 31 - 44

← 1 2 3 →